Antibody Industry Trends

For decades, the blood-brain barrier (BBB) was believed to be a shield that restricted efficient penetration of large antibody therapeutics from the central nervous system. This perception limited efforts to treat neurological diseases with biologics.

Monoclonal antibody (mAb) cost and accessibility challenges have fueled the development of biosimilars: biologic products designed to be copies of the reference mAb, but are often slightly different in pharmacodynamic and pharmacokinetic properties because of changes in glycosylation.

Antibody conjugates extend the therapeutic potential of monoclonal antibodies by linking them to diverse payloads, broadening their mechanisms of action.

Recent advances in high-throughput technologies are reshaping the antibody discovery landscape, with platforms now capable of rapidly producing highly specific, naturally paired antibodies. As reviewed by Wang et al. (2025), antibody library display systems (phage, yeast, bacterial, and ribosome dis

Antibody–drug conjugates (ADCs) merge the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Central to this system is the linker: a molecular bridge that dictates not only the stability of the ADC in circulation but also the precision and kinetics of payload r

Multispecific antibodies are increasingly being explored in the pharmaceutical industry for unmet patient needs, reshaping therapeutic possibilities by targeting multiple disease pathways simultaneously.

This August, we have seen several exciting antibody drug development announcements across Breakthrough Therapy, Fast Track, and Orphan Drug designations from regulatory agencies.Breakthrough Therapy Designations (BTDs): ADCs Drive Oncology InnovationOn August 27, Genmab announced BTD for

The last decade has seen a dramatic shift in the strategic development of antibody-based therapeutics for infectious diseases. Monoclonal antibodies (mAbs) have emerged as central agents in pandemic preparedness and the treatment of resistant infections. Driven by technological advances in sequencin

Sjögren’s disease (SjD) is a chronic, systemic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, most commonly the salivary and lacrimal glands, often accompanied by multi-organ extra-glandular involvement. Despite its substantial morbidity, therapeutic intervention

Immune cell engagers (ICEs) are engineered molecules that redirect endogenous immune effector cells toward malignant targets by forming synthetic immune synapses.

Trispecific antibodies are engineered proteins that can bind to three different targets at the same time. This design allows for more complex interactions than monospecific or bispecific antibodies and can be used to improve targeting, immune cell engagement, or signaling modulation.

Angiogenesis plays a fundamental role in both physiological processes such as wound healing and reproduction, as well as in pathological contexts including tumor growth, progression, and metastasis. Vascular endothelial growth factor (VEGF) is a regulator of angiogenesis and has been a major focus i